A:
The Defense Health Agency (DHA) sent out the utilization data so that Pharmaceutical Manufacturers may calculate refunds due to pursuant to 32 CFR § 199.21 and to enable timely resolution of manufacturer disputes. The DHA resolved pending waiver/compromise requests when sending out letters for 1Q CY2008- 2Q CY2009. At the present time, the DHA is only considering compromise of debt resulting from increased billings of drugs covered by VARRs executed prior to January 28, 2008.